Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dipanjan Chowdhury, Ph.D.

Co-Author

This page shows the publications co-authored by Dipanjan Chowdhury and Alan D'Andrea.
Connection Strength

1.223
  1. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. Mol Cell. 2020 11 05; 80(3):410-422.e6.
    View in: PubMed
    Score: 0.225
  2. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat Cell Biol. 2020 01; 22(1):87-96.
    View in: PubMed
    Score: 0.213
  3. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018 11; 563(7732):522-526.
    View in: PubMed
    Score: 0.196
  4. MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife. 2014 Apr 30; 3:e02445.
    View in: PubMed
    Score: 0.144
  5. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 Apr; 126(7):1027-1036.
    View in: PubMed
    Score: 0.061
  6. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
    View in: PubMed
    Score: 0.060
  7. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968.
    View in: PubMed
    Score: 0.055
  8. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543.
    View in: PubMed
    Score: 0.055
  9. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459.
    View in: PubMed
    Score: 0.054
  10. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2):e1277308.
    View in: PubMed
    Score: 0.043
  11. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer. Radiat Oncol. 2016 Apr 27; 11:61.
    View in: PubMed
    Score: 0.041
  12. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
    View in: PubMed
    Score: 0.041
  13. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):17041-6.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.